Nephrocare Health Services Share Price | Nephrocare Health Services Stock Screener
NEPHROPLUS
Healthcare Service Provider
Share Price NSE
₹649.70
▲
5.95 (0.92%)
Share Price BSE
₹650.45
▲
8.35 (1.30%)
As of May 19, 2026, the Nephrocare Health Services share price (NSE: NEPHROPLUS) is ₹649.70 on NSE and ₹650.45 on BSE, up 0.92% from the previous close, with shares trading between ₹635.00 and ₹658.45, and a 52-week range of ₹449.15–₹649.70.
Check Nephrocare Health Services 52-week for the annual price range and momentum.
Use the Nephrocare Health Services stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Nephrocare Health Services Market Cap
₹6,461.40 Cr.
NEPHROPLUS P/E Ratio (TTM)
90.68
Nephrocare Health Services P/B Ratio
5.96
EPS (TTM)
₹8.28
Dividend Yield
-
Debt to Equity
0.53
NEPHROPLUS 52 Week High
₹649.70
Nephrocare Health Services 52 Week Low
₹449.15
Operating Margin
23.00%
Profit Margin
12.17%
NEPHROPLUS Revenue (TTM)
₹263.00
EBITDA
₹64.00
Net Income
₹32.00
Total Assets
₹997.00
Total Equity
₹584.00
Nephrocare Health Services Share Price Chart
Screen Nephrocare Health Services share price with an interactive chart. Analyse NEPHROPLUS price trends and volatility across different timeframes.
Nephrocare Health Services Company Profile - Fundamental Screener
Screen Nephrocare Health Services company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for NEPHROPLUS shares.
Sector
Healthcare Services
Industry
Healthcare Service Provider
Sub-Sector
Healthcare Service Provider
Segment
E
ISIN
INE428V01029
Nephrocare Health Services Balance Sheet Screener
Screen NEPHROPLUS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Total Assets | 997 | 806 | 666 | 571 | 428 |
| Current Assets | 545 | 390 | 324 | 285 | 178 |
| Fixed Assets | 396 | 356 | 239 | 205 | 192 |
| Liabilities | |||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 129 | 150 | 103 | 81 | 75 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||
| Total Equity | 584 | 414 | 389 | 396 | 259 |
| Share Capital | 2 | 2 | 5 | 5 | 4 |
| Reserves & Surplus | 579 | 409 | 384 | 387 | 245 |
Nephrocare Health Services Income Statement Screener - Profit & Revenue Analysis
Screen Nephrocare Health Services income statement and profit fundamentals.
Analyze NEPHROPLUS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Nephrocare Health Services share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec |
|---|---|---|---|---|---|
| Revenue | 263 | 250 | 234 | 223 | 203 |
| Expenses | 199 | 182 | 180 | 168 | 153 |
| EBITDA | 64 | 68 | 54 | 55 | 50 |
| Operating Profit % | 23.00% | 26.00% | 21.00% | 23.00% | 22.00% |
| Depreciation | 22 | 23 | 20 | 19 | 18 |
| Interest | 6 | 45 | 6 | 6 | 5 |
| Profit Before Tax | 36 | -1 | 29 | 30 | 26 |
| Tax | 4 | 9 | 5 | 5 | 6 |
| Net Profit | 32 | -10 | 24 | 25 | 20 |
| EPS | 3.43 | -1.12 | 13.10 | 140.89 | 2.47 |
Nephrocare Health Services Cash Flow Screener - Liquidity Fundamentals
Screen NEPHROPLUS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March |
|---|---|---|---|---|---|
| Operating Activities | 135 | 72 | 11 | 14 | 32 |
| Investing Activities | -125 | -52 | -76 | -130 | -62 |
| Financing Activities | 54 | 27 | 60 | 121 | 36 |
| Net Cash Flow | 65 | 47 | -5 | 6 | 5 |
Nephrocare Health Services Shareholding Pattern Screener
See Nephrocare Health Services shareholding pattern with promoter, FII, and DII holdings.
Check Nephrocare Health Services promoter holding and ownership changes for NEPHROPLUS on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Jul |
|---|---|---|---|
| Promoter Holding | 63.85% | 63.85% | 79.05% |
| FII Holding | 9.94% | 9.30% | 0.00% |
| DII Holding | 8.65% | 8.10% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% |
| Public Holding | 5.08% | 5.92% | 0.00% |
| Other Holding | 12.48% | 12.82% | 20.94% |
| Shareholder Count | 43,409 | 36 | 65 |
Nephrocare Health Services Share Dividend Screener - Share Yield Analysis
Check Nephrocare Health Services dividend history with payout and yield data.
View Nephrocare Health Services dividend details including ex-dates and amounts for NEPHROPLUS stock.
Nephrocare Health Services Stock Index Membership
See which indices include Nephrocare Health Services stock.
Check NEPHROPLUS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Nephrocare Health Services Market Events Screener - Corporate Actions
Get Nephrocare Health Services corporate actions including splits, bonuses, and buybacks.
Check Nephrocare Health Services stock events that may affect NEPHROPLUS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-19 | 2026-05-19 | Quarterly Result Announcement | NA | 21.67% |
| 2026-02-10 | 2026-02-10 | Quarterly Result Announcement | NA | 2.85% |
Nephrocare Health Services Competitors Screener - Peer Comparison
Screen NEPHROPLUS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Dr. Lal Path Labs | 26,857 | 52.67 | 2,763 | 8.15% | 510 | 62.76 |
| Vijaya Diagnostic Centre | 13,677 | 79.42 | 814 | 16.36% | 182 | 76.26 |
| Metropolis Healthcare | 10,965 | 57.48 | 1,646 | 22.25% | 185 | 62.39 |
| Thyrocare Technologies | 7,356 | 45.25 | 829 | 18.06% | 156 | 64.76 |
| Nephrocare Health Services | 6,461 | 90.68 | 770 | 33.97% | 67 | 75.08 |
| Krsnaa Diagnostics | 1,896 | 23.53 | 743 | 16.70% | 78 | 45.23 |
| Suraksha Diagnostic | 1,592 | 49.20 | 256 | 15.11% | 31 | 64.76 |
| 3B BlackBio DX | 1,177 | 20.25 | 112 | 28.72% | 48 | 56.71 |
| Health X Platform | 904 | 32.79 | 1,171 | -18.47% | -134 | 52.97 |
| One Global Service Provider | 872 | 14.01 | 148 | 134.60% | 19 | 39.94 |
Nephrocare Health Services Company Announcements - News Screener
Screen NEPHROPLUS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-17 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements | - |
| 2026-05-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-04 | Board Meeting Intimation for Intimation Of Board Meeting For Considering Audited Financial Results Of The Company. | - |
| 2026-04-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-03 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-04-02 | Announcement Under Regulation 30 (LODR)- Disclosure Of Litigation Filed By The Company | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-03-16 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-19 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-18 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-18 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-12 | Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements | - |
| 2026-02-12 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-02-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-10 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-02-10 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-02-10 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-02-10 | Board Meeting Outcome for Outcome Of The Board Meeting Held On February 10 2026 | - |
| 2026-02-07 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |